Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Schering and MediGene begin HPV vaccine trial

Nov. 23, 2000

European Commission grants orphan drug status to Mylotarg for treatment of AML

Nov. 16, 2000

Potential cellular mechanism for adverse cardiac effects of Herceptin described at AHA sessions

Nov. 16, 2000

Independent safety board recommends continuation of Theratope vaccine phase III trial

Nov. 15, 2000

York Medical acquires Norelin from Biostar

Nov. 14, 2000

Data presented at Heat Shock Proteins symposium support clinical application of HspE7

Nov. 10, 2000

First phase III trial of HspE7 commences in anal dysplasia

Nov. 9, 2000

Update on worldwide phase III trials of Maxamine

Nov. 9, 2000

Maxamine protects against IL-2 toxicity in murine model

Nov. 8, 2000

Seattle Genetics evaluates SGN-15/Taxotere combination in phase II

Nov. 7, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Sex differences shape gene activity across the human brain
BioWorld
Genes that are switched on or off in the human brain differ between men and women. Moreover, these differences are not uniform. They vary across cortical regions...
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
Gilead Sciences patents new GTPase KRAS G12D inhibitors
BioWorld Science
Gilead Sciences Inc. has disclosed new GTPase KRAS G12D mutant inhibitors potentially useful for the treatment of cancer.